A disintegrin and metalloprotease 17 promotes microglial cell survival via epidermal growth factor receptor signalling following spinal cord injury

Wei,Zijian; Yu,Deshui; Bi,Yunlong; Cao,Yang

doi:10.3892/mmr.2015.3395

A disintegrin and metalloprotease 17 promotes microglial cell survival via epidermal growth factor receptor signalling following spinal cord injury

Authors:
- Zijian Wei
- Deshui Yu
- Yunlong Bi
- Yang Cao
View Affiliations

Affiliations: Graduate School of Liaoning Medical University, Jinzhou, Liaoning 121001, P.R. China, Department of Orthopedics, The First Affiliated Hospital of Liaoning Medical University, Jinzhou, Liaoning 121001, P.R. China
Published online on: February 27, 2015 https://doi.org/10.3892/mmr.2015.3395
Pages: 63-70
Copyright: © Wei et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumour necrosis factor‑α (TNF‑α) converting enzyme (TACE), also termed a disintegrin and metalloprotease 17 (ADAM17), is involved in multiple cell signalling pathways. Through the secretion of epidermal growth factor receptor (EGFR) ligands, ADAM17 can activate the EGFR and is involved in various downstream signalling pathways. The present study aimed to investigate whether ADAM17‑induced EGFR transactivation is involved in microglial cell survival following spinal cord injury (SCI). Reverse transcription quantitative polymerase chain reaction and western blot analysis revealed that ADAM17 was overexpressed in a mouse model following SCI. A 3‑(4,5‑dimethylthiazol‑2‑yl)‑2,5‑diphenyltetrazolium bromide assay demonstrated that the viability of human microglia and oligodendrocytes were significantly reduced in a time‑ and dose‑dependent manner following treatment with the ADAM17 antagonist, TNF protease inhibitor 2. Hoechst 33258 staining and flow cytometric analysis revealed that inhibiting ADAM17 increased the rate of cellular apoptosis in neuronal and glial cell cultures, which was accompanied by increased cleavage of caspase‑3. Western blot analysis demonstrated that inhibiting ADAM17 resulted in a reduction in the phosphorylation of the EGFR signalling pathway components and thereby impaired functional recovery, inhibited cell viability and prompted microglial apoptosis following SCI. Pre‑treatment with the EGFR inhibitor, AG1478, rescued the ADAM17‑mediated proliferation of microglial cells. These data demonstrated that ADAM17 contributed to microglial cell survival, predominantly by EGFR signalling, following SCI.

View Figures

View References

1	Vidal PM, Lemmens E, Avila A, et al: ADAM17 is a survival factor for microglial cells in vitro and in vivo after spinal cord injury in mice. Cell Death Dis. 4:e9542013. View Article : Google Scholar : PubMed/NCBI
2	Aghababaei M, Perdu S, Irvine K and Beristain AG: A disintegrin and metalloproteinase 12 (ADAM12) localizes to invasive trophoblast, promotes cell invasion and directs column outgrowth in early placental development. Mol Hum Reprod. 20:235–249. 2014. View Article : Google Scholar
3	Murthy A, Defamie V, Smookler DS, et al: Ectodomain shedding of EGFR ligands and TNFR1 dictates hepatocyte apoptosis during fulminant hepatitis in mice. J Clin Invest. 120:2731–2744. 2010. View Article : Google Scholar : PubMed/NCBI
4	Wang X, Feuerstein GZ, Xu L, et al: Inhibition of tumor necrosis factor-alpha-converting enzyme by a selective antagonist protects brain from focal ischemic injury in rats. Mol Pharmacol. 65:890–896. 2004. View Article : Google Scholar : PubMed/NCBI
5	Oyinbo CA: Secondary injury mechanisms in traumatic spinal cord injury: a nugget of this multiply cascade. Acta Neurobiol Exp (Wars). 71:281–299. 2011.
6	Wang XJ, Feng CW and Li M: ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway. Mol Cell Biochem. 380:57–66. 2013. View Article : Google Scholar : PubMed/NCBI
7	Saxena R, Chandra V, Manohar M, et al: Chemotherapeutic potential of 2-(piperidinoethoxyphenyl)-3-phenyl-2H-benzo(b) pyran in estrogen receptor- Negative breast cancer cells: action via prevention of EGFR activation and combined inhibition of PI-3-K/Akt/FOXO and MEK/Erk/AP-1 pathways. PLoS One. 8:e662462013. View Article : Google Scholar
8	Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
9	Shen Q, Uray IP, Li Y, et al: Targeting the activator protein 1 transcription factor for the prevention of estrogen receptor-negative mammary tumors. Cancer Prev Res (Phila). 1:45–55. 2008. View Article : Google Scholar
10	Li Z, Zhang H, Chen Y, Fan L and Fang J: Forkhead transcription factor FOXO3a protein activates nuclear factor kappaB through B-cell lymphoma/leukemia 10 (BCL10) protein and promotes tumor cell survival in serum deprivation. J Biol Chem. 287:17737–17745. 2012. View Article : Google Scholar : PubMed/NCBI
11	Yin XM: Signal transduction mediated by Bid, a pro-death Bcl-2 family proteins, connects the death receptor and mitochondria apoptosis pathways. Cell Res. 10:161–167. 2000. View Article : Google Scholar : PubMed/NCBI
12	Seals DF and Courtneidge SA: The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 17:7–30. 2003. View Article : Google Scholar : PubMed/NCBI
13	Ware CF, VanArsdale S and VanArsdale TL: Apoptosis mediated by the TNF-related cytokine and receptor families. J Cell Biochem. 60:47–55. 1996. View Article : Google Scholar : PubMed/NCBI
14	Beattie MS, Harrington AW, Lee R, et al: ProNGF induces p75-mediated death of oligodendrocytes following spinal cord injury. Neuron. 36:375–386. 2002. View Article : Google Scholar : PubMed/NCBI
15	Micheau O and Tschopp J: Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 114:181–190. 2003. View Article : Google Scholar : PubMed/NCBI
16	Zhang J, Geula C, Lu C, Koziel H, Hatcher LM and Roisen FJ: Neurotrophins regulate proliferation and survival of two microglial cell lines in vitro. Exp Neurol. 183:469–481. 2003. View Article : Google Scholar : PubMed/NCBI
17	Chalaris A, Adam N, Sina C, et al: Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. J Exp Med. 207:1617–1624. 2010. View Article : Google Scholar : PubMed/NCBI
18	Tuszynski MH and Steward O: Concepts and methods for the study of axonal regeneration in the CNS. Neuron. 74:777–791. 2012. View Article : Google Scholar : PubMed/NCBI
19	Liang X, Yang Y, Deng C, et al: The variation of Caspase3 activity in tanshinone induced NB4 cells apoptosis. Sichuan Da Xue Xue Bao Yi Xue Ban. 34:549–551. 2003.In Chinese. PubMed/NCBI
20	Zheng X, Jiang F, Katakowski M, et al: Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell invasiveness. Cancer Sci. 98:674–684. 2007. View Article : Google Scholar : PubMed/NCBI
21	Ebsen H, Schroder A, Kabelitz D and Janssen O: Differential surface expression of ADAM10 and ADAM17 on human T lymphocytes and tumor cells. PLoS One. 8:e768532013. View Article : Google Scholar : PubMed/NCBI
22	Etzerodt A, Maniecki MB, Moller K, Moller HJ and Moestrup SK: Tumor necrosis factor alpha-converting enzyme (TACE/ADAM17) mediates ectodomain shedding of the scavenger receptor CD163. J Leukoc Biol. 88:1201–1205. 2010. View Article : Google Scholar : PubMed/NCBI
23	Nieto-Sampedro M, Gomez-Pinilla F, Knauer DJ and Broderick JT: Epidermal growth factor receptor immunore-activity in rat brain astrocytes. Response to injury Neurosci Lett. 91:276–282. 1988.
24	Hassemer EL, Endres B, Toonen JA, Ronchetti A, Dubielzig R and Sidjanin DJ: ADAM17 transactivates EGFR signaling during embryonic eyelid closure. Invest Ophthalmol Vis Sci. 54:132–140. 2013. View Article : Google Scholar :
25	Parker WE, Orlova KA, Heuer GG, et al: Enhanced epidermal growth factor, hepatocyte growth factor, and vascular endothelial growth factor expression in tuberous sclerosis complex. Am J Pathol. 178:296–305. 2011. View Article : Google Scholar : PubMed/NCBI
26	Fischer OM, Hart S and Ullrich A: Dissecting the epidermal growth factor receptor signal transactivation pathway. Methods Mol Biol. 327:85–97. 2006.PubMed/NCBI
27	Battersby S, Sales KJ, Williams AR, et al: Seminal plasma and prostaglandin E2 up-regulate fibroblast growth factor 2 expression in endometrial adenocarcinoma cells via E-series prostanoid-2 receptor-mediated transactivation of the epidermal growth factor receptor and extracellular signal-regulated kinase pathway. Hum Reprod. 22:36–44. 2007. View Article : Google Scholar
28	Xu L, Huang Y, Yu X, Yue J, Yang N and Zuo P: The influence of p38 mitogen-activated protein kinase inhibitor on synthesis of inflammatory cytokine tumor necrosis factor alpha in spinal cord of rats with chronic constriction injury. Anesth Analg. 105:1838–1844, table of contents. 2007. View Article : Google Scholar : PubMed/NCBI
29	Koistinaho M and Koistinaho J: Role of p38 and p44/42 mitogen-activated protein kinases in microglia. Glia. 40:175–183. 2002. View Article : Google Scholar : PubMed/NCBI
30	Benakis C, Bonny C and Hirt L: JNK inhibition and inflammation after cerebral ischemia. Brain Behav Immun. 24:800–811. 2010. View Article : Google Scholar
31	Villapol S, Acarin L, Faiz M, Castellano B and Gonzalez B: Distinct spatial and temporal activation of caspase pathways in neurons and glial cells after excitotoxic damage to the immature rat brain. J Neurosci Res. 85:3545–3556. 2007. View Article : Google Scholar : PubMed/NCBI
32	Koprivica V, Cho KS, Park JB, et al: EGFR activation mediates inhibition of axon regeneration by myelin and chondroitin sulfate proteoglycans. Science. 310:106–110. 2005. View Article : Google Scholar : PubMed/NCBI